READ THE FULL BSEM RESEARCH REPORT
BioStem Technologies, Inc. (OTC:BSEM) is a leading innovator focused on harnessing the natural properties of perinatal tissue in the development, manufacture, and commercialization of allografts for regenerative therapies. The company states its mission is “to discover, develop and produce the most effective regenerative medicine products in the world,” and we believe that the company is well on its way to achieving that goal—providing to investors what we believe is an opportunity to invest in a company that is both providing a vital service to the human population and providing economic value to shareholders when doing so.
The company faced challenges in 2Q2025 as it saw a loss of $0.03 per share on a 34% decrease in revenues. Margins remain extremely strong and improved to 98.6% of revenue, and the company has good cash on the balance sheet as it rose to $30.8 million from $20.6 million in the quarter earlier period. Preliminary financial results were released, preventing the update of the full financial statement at this time. As a result of the disappointing quarter and uncertainty surrounding reimbursements, we are lowering our price target to $25.50.
Management addressed the MACS LCD issue, which was most of the cause of the decrease in revenue, as uncertainty surrounding product reimbursement by Medicare caused a drop in purchases. The company noted it continues to work hard at making sure the review process is fair, and their products are understood, and we continue to believe the company will ultimately be successful in getting Vendaje and Vendaje AC covered, and patients will continue to have access to the superior products that many patients have received.
The company also recently announced patient enrollment was completed for the testing of BioREtain Amnion Chorion for the treatment of diabetic foot ulcers, with readouts expected in the fourth quarter of 2025. BioStem continues to demonstrate that its products, including Vendaje and Vendaje AC, outperform existing products and are drawing increasing interest from doctors and patients, which is why we continue to have a positive view on BSEM.
Given these developments and our belief that the company will be successful in its LCD coverage issue and continue to expand access to its superior wound care products, we believe the best for BSEM is still to come and urge investors to be patient.
Summary
We reiterate our belief in the direction of BSEM and our strong appreciation for the way management has navigated challenges and grown the company in a smart fashion and urge investors to take a look at the stock and consider adding it to a portfolio.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.
